Summary
Biotron Ltd (BIT) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biotron Ltd ever had a stock split?
Biotron Ltd Profile
| Biotechnology Industry | Healthcare Sector | Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D. CEO | ASX Exchange | Q1527U107 CUSIP |
| Australia Country | - Employees | - Last Dividend | 5 Mar 2025 Last Split | - IPO Date |
Overview
Biotron Limited is an Australian biotechnology company founded in 1999, primarily focused on the development and commercialization of novel small molecule treatments aimed at various viral diseases. With its headquarters based in Sydney, Australia, Biotron stands at the forefront of antiviral research, dedicating its resources to bringing innovative therapeutic options to patients suffering from viral infections. The company's approach involves the identification and development of drugs with the potential to significantly impact the current treatment landscape for viruses such as SARS-CoV-2, HIV-1, and hepatitis C.
Products and Services
-
BIT225
Biotron's flagship product, BIT225, represents a significant advancement in the treatment of viral infections, focusing on three major viruses: SARS-CoV-2, responsible for the COVID-19 pandemic; HIV-1, the most common and pathogenic strain of the human immunodeficiency virus; and the hepatitis C virus, a leading cause of liver disease worldwide. Currently, BIT225 is undergoing Phase II clinical trials, highlighting its potential as a versatile antiviral drug. The development of BIT225 underscores Biotron's commitment to addressing urgent global health challenges by targeting key mechanisms of viral replication and disease progression.
